Please assess the completion status of the following clinical trial:

Trial Title: Methotrexate-Inadequate Response Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com~Inclusion Criteria:~* Subjects who are considered methotrexate inadequate responders~* 10 or more swollen joints (66 joint count) and 12 or more tender joints (68 joint count)~Exclusion Criteria:~* Subjects who failed one or multiple anti-tumor necrosis factor (TNF) therapies~* Subjects who meet diagnostic criteria for any other rheumatic disease (e.g., lupus erythematous)~* Subjects with active vasculitis of a major organ system (except for subcutaneous rheumatoid nodules)~* Subjects with severe chronic or recurrent bacterial infections~* Subjects who have received treatment with rituximab~An Anti-TNF Failure Sub-study was initiated (recruited separately from Main study) using the same treatment as the Main study in order to assess the immunogenicity and safety in the Anti-TNF Failure population. The Sub-study terminated due to low recruitment and participants were permitted to roll into the LT Open Label Period.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Subcutaneous (SC) Abatacept (Type: ACTIVE_COMPARATOR): Participants received 125 mg weekly SC abatacept injections (with an intravenous \[IV\] abatacept loading dose on Day 1, based on weight). A double-dummy design was used to protect the blind, thus, participants also received IV injections of placebo (IV Placebo) with the exception that on Day 1 a loading dose of IV abatacept replaced the IV Placebo treatment.
- Intravenous (IV) Abatacept (Type: ACTIVE_COMPARATOR): Participants received IV abatacept infusions on Days 1, 15, 29, and every 28 days, thereafter. A double-dummy design was used to protect the blind, thus, participants also received SC injections of placebo (SC Placebo).

Based on this trial design, predict the completion outcome and termination type (if applicable).